Atif Jalees Khan, MD, MS
Radiation Therapy for Early and Advanced Breast Cancer, Primary and Secondary Brain Tumors; Brachytherapy; Proton Therapy; Stereotactic Cranial and Extracranial Radiotherapy
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Khan accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
Memorial Sloan Kettering is a designated Blue Distinction Center for bone marrow transplant and CAR-T.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment. In-network participation exceptions include:
- Emblem’s HIP Commercial Millennium, Select Care and Enhanced Care Prime networks is not in-network with Memorial Sloan Kettering.
- Please call Emblem to confirm if your specific plan is in-network.
For information regarding Memorial Sloan Kettering’s participation with Emblem’s Medicare Advantage Plans, please refer to the Medicare & Medicaid page
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York Indemnity, HMO, EPO, PPO, POS and Medicare Advantage plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Please call Empire BCBS to confirm if your specific plan is in-network with Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
For our NJ locations, Memorial Sloan Kettering is an in-network provider with most Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. Horizon members with Blue Card Access (there would be a suitcase logo on the front of the card) may have access to our NY locations. Please call Horizon to confirm if your plan is in-network in NY.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
For information about Medicare and Medicaid, please visit this page
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
Most Blue Cross Blue Shield plans include Memorial Sloan Kettering as an in-network provider. Contact your insurance company to confirm if Memorial Sloan Kettering is in-network.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
MS, Radiological Sciences, Rush University - The Graduate College; MS, Clinical & Translational Science, Rutgers Graduate School of Biomedical Sciences; MD, Aga Khan University Medical College
Rush University Medical Center
Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School
I am a radiation oncologist who specializes in caring for people with breast cancer, brain tumors, and soft tissue sarcomas. I am experienced in using advanced treatment techniques, such as brachytherapy, proton therapy, and stereotactic radiation therapy. My experience allows me to offer the people I care for a plan that best suits their diagnosis and treatment goals.
Radiation oncology is in the middle of a technology revolution. We are creating new tools and techniques that can deliver treatment at a precise level we never could have imagined before. We have also come a long way in understanding the biology of various cancers. All of this means that many people with cancer have better outcomes with fewer side effects. I’m excited to be a part of this progress as a member of the Memorial Sloan Kettering team. MSK combines cutting-edge treatment and research with a history of excellence like no other.
I am heavily involved in clinical and translational research, particularly for breast cancer. Many of the studies I am currently leading are national and multi-institutional. These trials will fundamentally affect how we treat and think about breast cancer.
Among the studies I’m involved with are studies of accelerated breast radiation. In a currently open trial, we are studying if we can safely compress treatment down to 5 visits (MSK trial 20-513) in women who have had mastectomy with reconstruction.
Other research I’m involved in focuses on women with triple negative breast cancer. One trial studies whether radiation therapy can make immunotherapy work better in women whose disease has spread to other parts of the body, particularly for women who are not thought to be good candidates for immunotherapy or whose disease has started to grow on immunotherapy (MSK trial 20-505).
Please contact my office for additional details on these trials.
Receiving a diagnosis complicates the lives of people with cancer and their caregivers in many unanticipated ways. I experienced this firsthand when my mother was treated for breast cancer. I remember how much my parents valued her doctor’s time and having a personal connection as they navigated the unfamiliar world of hospitals and treatment centers. My experience with my family influences how I care for people with cancer, and I feel privileged to be a part of their lives.
My experience with my family influences how I care for people with cancer, and I feel privileged to be a part of their lives.
- Clinical Trials Investigated by Dr. Khan
- A Phase I Study of Rucaparib plus Radiation Therapy in Women with Triple-Negative Breast Cancer Who Did Not Respond Completely to Presurgical Chemotherapy
- A Phase II Study of Radiation Therapy with Pembrolizumab Immunotherapy and Olaparib in Women with Triple-Negative Breast Cancer
- A Phase II Study of Three-Day Partial Breast Radiation Therapy in Women with Breast Cancer
- A Study Assessing a Shortened Radiation Therapy Schedule in People Who Had a Mastectomy for Early Breast Cancer
- A Study Assessing the Addition of Pembrolizumab Immunotherapy and Radiation Therapy to Standard Chemotherapy Before Surgery in People with Breast Cancer
- Clinical Trials Co-Investigated by Dr. Khan
- A Phase III Study Evaluating of the Role of Axillary (Armpit) Lymph Node Removal in Patients with Breast Cancer with Positive Sentinel Lymph Nodes after Preoperative Chemotherapy
- A Study Assessing the Need for Regional Radiation Therapy in Women with Low-Risk Breast Cancer
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Haffty BG, Harrold E, Khan A, Pathare P, Ward BA, Matloff E, Alvarez-Franco M, Bale AE. (2002). Conservatively Managed Breast Cancer in Young Women: Outcome as a Function of BRCA 1/2 Status. Lancet, 27;359(9316),1471-7.
Khan AJ, Mehta PS, Zusag TW, Bonomi PD , Faber LP, Abrams RA. (2006). Long term disease-free survival resulting from combined modality management of patients presenting with oligometastic, non-small cell lung carcinoma (NSLCL). Radiother Oncol, 81(2),163-7.
Khan AJ, Wall B, Ahlawat S, Green C, Schiff D, Mehnert JM, Goydos JS, Chen S, Haffty BG. (2011). Riluzole Enhances Ionizing Radiation-induced Cytotoxicity in Human Melanoma Cells that Ectopically Express Metabotropic Glutamate Receptor In Vitro and In Vivo. Clinical Cancer Research, 17(7), 1807-14.
Khan AJ, Vicini FA, Brown S, Haffty BG, Kearney T, Dale R, Lyden M, and Arthur D. (2013) Dosimetric Feasibility and Acute Toxicity in a Prospective Trial of Ultra-short Course Accelerated Partial Breast Irradiation (APBI) using a Multi-Lumen Balloon Brachytherapy Device. Ann Surg Oncol. 20(4):1295-301.
Khan AJ, Rafique R, Zafar W, Shah C, Haffty BG, Vicini F, Jamshed A, Zhao Y. (2017) Nation-Scale Adoption of Shorter Breast Radiotherapy Schedules Can Increase Survival in Resource Constrained Economies: Results from a Markov Chain Analysis. Int J Radiat Oncol Biol Phys. 97(2):287-295. doi: 10.1016/j.ijrobp.2016.10.002. Pubmed PMID: 27986343.
Khan AJ, Poppe M, Goyal S, Kokeny KE, Kearney T, Kirstein L, Toppmeyer D, Moore DF, Chen C, Gaffney DK, Haffty BG. (2017) Hypofractionated Post-Mastectomy Radiation Therapy is Safe and Effective: First Results from a Prospective Phase II Trial. J Clin Oncol. In press.
Visit PubMed for a full listing of Dr. Khan’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Atif Jalees Khan discloses the following relationships and financial interests:
Ownership / Equity Interests
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.